Group 1 - The latest Fortune Global 500 list includes 130 Chinese companies, with 12 headquartered in Shanghai [1] - Pinduoduo has shown rapid revenue growth, ranking as the fastest rising Chinese company on the list, moving from 442nd to 266th place, an increase of 176 positions [1] - Pinduoduo's total revenue for 2024 reached 393.84 billion yuan, a year-on-year increase of 59%, driven by a significant rise in transaction service revenue [1] Group 2 - Pinduoduo topped the Chinese companies' ROE (Return on Equity) ranking, with a net profit of 112.44 billion yuan, a substantial increase of 87% year-on-year [2] - China Pacific Insurance also saw a notable rise in ranking, moving from 331st to 251st, with a revenue of 404.09 billion yuan, up 24.7% year-on-year [2] - Other Shanghai-based companies on the list include China Baowu, SAIC Motor, and COSCO Shipping, with several having been on the list for over a decade [2]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for clinical trials of its B019 injection for the treatment of refractory systemic lupus erythematosus, marking a significant step in its drug development process [1][2]. Group 1: Project Basic Information - The drug B019 is a chimeric antigen receptor (CAR) T-cell injection targeting CD19 and CD22, designed for refractory systemic lupus erythematosus [2]. - The clinical trial application for B019 was accepted on April 29, 2025, under registration number CXSL2500344, and the approval notice number is 2025LP01884 [1][2]. Group 2: R&D and Registration Status - B019 has previously received approvals for clinical trials targeting relapsed or refractory acute B-cell leukemia and relapsed or refractory B-cell non-Hodgkin lymphoma, with applications approved in October 2023 and December 2024, respectively [2]. - The project is developed independently by Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Biotherapy, which holds complete intellectual property rights [2]. - As of the announcement date, approximately 149,000 RMB has been invested in the R&D of the new indication [2]. Group 3: Market Situation - As of the announcement date, there are no other drugs on the market targeting the same indication with the same mechanism [3]. Group 4: Impact on the Company - The approval for B019's new indication does not have a significant immediate impact on the company's operations, but the company will actively promote the project in accordance with national regulations and fulfill information disclosure obligations regarding future progress [4].

证券代码：601607 证券简称：上海医药 编号：临2025-076 上海医药集团股份有限公司 关于 B019 新适应症获得临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海医药集团生物治疗技术有限公司（以下简称"上药生物治疗"）自主研发 的"B019"（以下简称"B019 注射液"或"该项目"）收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的《药物临床试验批准通知书》，同意其开 展难治性系统性红斑狼疮（以下简称"新适应症"）的临床试验。现将有关情况 公告如下： 一、该项目基本信息 药物名称：靶向 CD19 和 CD22 的嵌合抗原受体自体 T 细胞注射液 剂型：注射剂 申请事项：境内生产药品注册临床试验 受理号：CXSL2500344 通知书编号：2025LP01884 上海医药集团股份有限公司 二、该项目研发及注册情况 B019 注射液是靶向 CD19 和 CD22 的嵌合抗原受体自体 T 细胞注射液，拟用 ...

Group 1 - Heartway Medical-B (06609.HK) expects a net profit of no less than RMB 40 million for the six months ending June 30, 2025, a significant turnaround from a net loss of approximately RMB 5.1 million for the corresponding period ending June 30, 2024 [1] - The anticipated profit and performance improvement are primarily due to business growth, leading to increased revenue and a decrease in overall expenditure ratio compared to the corresponding period [1] Group 2 - Baoshan International (03813.HK) expects a mid-term net profit of approximately RMB 187.6 million, a year-on-year decrease of 44.1% [2] - Baio Family Interaction (02100.HK) anticipates a mid-term profit increase of approximately 134.9% to 141.6% [2] - Skyworth Group (00751.HK) warns of an expected mid-term post-tax profit decline of about 50% year-on-year [2] Group 3 - China CNR Corporation (01766.HK) recently signed a significant contract worth approximately RMB 32.92 billion [2] - China Power (02380.HK) reported a total electricity sales volume of 11.299 million megawatt-hours in June, a year-on-year decrease of 5.04% [2]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), received a Supplementary Application Approval Notice from the National Medical Products Administration for its Salbutamol Sulfate Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Salbutamol Sulfate Injection is primarily used for treating bronchial asthma or wheezing bronchitis and other respiratory diseases associated with bronchospasm [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of its self-developed drug "B019" for the treatment of refractory systemic lupus erythematosus [1] Group 1 - The clinical trial approval allows the company to advance its research on B019, which targets a significant unmet medical need in the treatment of systemic lupus erythematosus [1] - B019 is positioned as a potential innovative therapy in the biopharmaceutical sector, reflecting the company's commitment to developing new treatments [1] - The approval marks a critical milestone in the drug development process, potentially leading to future commercialization opportunities for the company [1]

人民财讯7月29日电，上海医药（601607）7月29日晚间公告，公司下属上药生物治疗自主研发 的"B019"收到国家药监局核准签发的《药物临床试验批准通知书》，同意其开展难治性系统性红斑狼 疮(简称"新适应症")的临床试验。 ...

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for clinical trials of its self-developed B019 injection, aimed at treating refractory systemic lupus erythematosus [2]. Company Summary - B019 injection is a chimeric antigen receptor T-cell injection targeting CD19 and CD22, intended for the treatment of refractory systemic lupus erythematosus [2]. - The drug has previously been approved for clinical trials for two other indications: relapsed or refractory acute B-cell leukemia and relapsed or refractory B-cell non-Hodgkin lymphoma, with approvals granted in October 2023 and December 2024, respectively [2].

Core Viewpoint - Shanghai Pharmaceuticals (601607) has received approval from the National Medical Products Administration for its self-developed drug "B019" to conduct clinical trials for refractory systemic lupus erythematosus [1] Group 1: Product Development - B019 is a chimeric antigen receptor (CAR) T-cell injection targeting CD19 and CD22, intended for the treatment of refractory systemic lupus erythematosus [1] - The CAR structure of B019 utilizes a dual promoter vector, allowing T-cells to express two independent CARs that can bind to CD19 or CD22 proteins on B lymphocytes without interference [1] Group 2: Clinical Trial Approvals - Clinical trial applications for B019 to treat relapsed or refractory acute B-cell leukemia and relapsed or refractory B-cell non-Hodgkin lymphoma have been approved by the National Medical Products Administration in October 2023 and December 2024, respectively [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) has received approval from the National Medical Products Administration for its self-developed drug "B019" to conduct clinical trials for refractory systemic lupus erythematosus [1] Group 1: Product Development - B019 is a chimeric antigen receptor (CAR) T-cell injection targeting CD19 and CD22, intended for the treatment of refractory systemic lupus erythematosus [1] - The CAR structure of B019 utilizes a dual promoter vector, allowing T-cells to express two independent CARs that can bind to CD19 or CD22 proteins on B lymphocytes without interference [1] Group 2: Clinical Trial Approvals - Clinical trial applications for B019 to treat relapsed or refractory acute B-cell leukemia and relapsed or refractory B-cell non-Hodgkin lymphoma were approved by the National Medical Products Administration in October 2023 and December 2024, respectively [1]